Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02515331 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Phase 2 study of Patients, Resistant Hypertension, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 16
- Study locations
NCT02515331 is a Phase 2 study of Patients, Resistant Hypertension that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 64 participants. The trial reports 16 study locations across 7 states.
The verdict
NCT02515331, a Phase 2 study of Patients, Resistant Hypertension, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LHW090
Study Locations (16)
Other
- Novartis Investigative Site - Gentofte Municipality
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Düsseldorf
- Novartis Investigative Site - Hanover
- Novartis Investigative Site - Homburg
- Novartis Investigative Site - Basel
- Novartis Investigative Site - Lausanne
Florida
- Novartis Investigative Site - Atlantis
- Novartis Investigative Site - Daytona Beach
- Novartis Investigative Site - Jacksonville
Alabama
- Novartis Investigative Site - Birmingham
California
- Novartis Investigative Site - North Hollywood
Hawaii
- Novartis Investigative Site - Honolulu
Tennessee
- Novartis Investigative Site - Knoxville
Netherlands
- Novartis Investigative Site - Meibergdreef 9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-11-04 |
| Est. Completion | 2017-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02515331
The ClinicalTrials.gov registry entry for NCT02515331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patients, Resistant Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02515331 reports 16 study locations spanning 7 distinct geographic areas - top geographies include Other, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT02515331 about?
NCT02515331 is a clinical study titled "Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients". The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
What is the current status of trial NCT02515331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2015-11-04. Estimated completion is 2017-08-17.
What conditions does trial NCT02515331 study?
This clinical trial studies the following conditions: Patients, Resistant Hypertension.
What interventions are being tested in trial NCT02515331?
The interventions under investigation include: Placebo (DRUG), LHW090 (DRUG).
Who is sponsoring clinical trial NCT02515331?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02515331 being conducted?
This trial has 16 study locations across Alabama, California, Florida, Hawaii, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.